Publication
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
Journal Paper/Review - Mar 15, 2019
Putora Paul Martin, Nestle Ursula, Novello Silvia, Brien Mary O', Paz Ares Luis, Peeters Stephanie, Pöttgen Christoph, Ramella Sara, Reck Martin, Troost Esther G C, Van Houtte Paul, Westeel Virginie, Widder Joachim, Mornex Francoise, McDonald Fiona, Le Pechoux Cecile, Glatzer Markus, De Ruysscher Dirk, Faivre-Finn Corinne, Belderbos Jose, Besse Benjamin, Blackhall Fiona, Califano Raffaele, Cappuzzo Federico, de Marinis Filippo, Dziadiuszko Rafal, Felip Enriqueta, Früh Martin, Garrido Pilar, Slotman Ben J
Units
PubMed
Doi
Citation
Type
Journal
Publication Date
Issn Electronic
Pages
Brief description/objective
BACKGROUND
The role of consolidative thoracic radiotherapy (TRT) in stage IV small cell lung cancer (SCLC) is not uniformly accepted.
METHODS
We obtained a list of 13 European medical oncologists from the International Association for the Study of Lung Cancer (IASLC) and 13 European radiation oncologists from the European Society for Therapeutic Radiation Oncology (ESTRO). The strategies in decision making for TRT in stage IV SCLC were collected. Decision trees were created representing these strategies. Frequencies of recommending TRT were analysed for various parameter combinations based on the objective consensus methodology.
RESULTS
The factors associated with the recommendation for TRT included fitness of the patient, limited extrathoracic tumour burden, initial bulky thoracic disease and response to chemotherapy. The highest consensus for TRT was in fit patients with limited extrathoracic tumour burden and initial bulky disease with either a complete extrathoracic response or partial thoracic response (92% recommend TRT). For these patients the recommendations were the same for medical and radiation oncologists. In the setting of partial response (intra- and extra-thoracically) without initial bulky thoracic disease radiation oncologists were more likely to recommend TRT than medical oncologists. For unfit patients or for patients with poor overall response to chemotherapy, the majority did not recommend TRT.
CONCLUSION
European radiation and medical oncologists specializing in lung cancer recommend TRT in selected patients with stage IV SCLC and restrict its use primarily to fit patients who responded to chemotherapy with limited extrathoracic tumour burden.